Lorbrena (Lorlatinib)

Lorbrena is called Lorbiqua or Lorbriqua internationally.  Save 68% on brand name medicine by Pfizer!

EU Lorviqua/Lorbriqua is manufactured at: Pfizer Manufacturing Deutschland GmbH Betriebsstӓtte Freiburg Mooswaldallee 1 79090 Freiburg Germany

Lorbriqua is manufactured at above address or alternatively at:

Pfizer Pharmaceuticals LLC; KM 1.9 Road 689, Vega Baja, Puerto Rico - 00693, United States (USA)

• EU APPROVAL - showing manufacturing site
• Lorbriqua - Pfizer medicine insert showing manufacturing in German or USA for Lorbriqua

Information about Lorbrena (Lorlatinib)

Lorbrena is an oral medication that belongs to a class of drugs known as tyrosine kinase inhibitors. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) that is ALK-positive.

Product Highlights

• Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive, especially after progression on other ALK inhibitors.

Key Ingredient

• Lorlatinib

Key Benefits

• Effective in patients with ALK-positive NSCLC, particularly those who have previously received treatment.
• May help in managing brain metastases due to its ability to penetrate the blood-brain barrier.
• Can improve overall survival and quality of life for patients with advanced disease.

Direction of Use

• Take Lorbrena exactly as prescribed by your healthcare provider.
• The typical dosage is one tablet taken once a day, with or without food.
• Take the tablet whole; do not crush or chew it.
• Follow your healthcare provider's instructions regarding any missed doses.

Safety Concerns

• Common side effects may include fatigue, nausea, diarrhea, and elevated liver enzymes.
• Potential for serious side effects like pneumonitis, hyperlipidemia, and central nervous system effects.
• Frequent monitoring of liver function and lipid levels may be necessary during treatment.

Avoid Lorbrena (Lorlatinib) If

• You are allergic to lorlatinib or any of the inactive ingredients in the formulation.
• You have severe liver disease.
• You are taking medications that may interact with lorlatinib, unless advised by a healthcare provider.
• You are pregnant or planning to become pregnant, as it may harm the fetus.